Status:
UNKNOWN
Clinical Study on the Efficacy of Microvascular Decompression in the Treatment of Neurogenic Hypertension
Lead Sponsor:
Peking University People's Hospital
Conditions:
Neurogenic Hypertension
Hypertension
Eligibility:
All Genders
18+ years
Brief Summary
Hypertension has always been a threat to human health, so the prevention and treatment is of great significance. At present, the treatment of primary hypertension is mainly drug treatment, but many pa...
Detailed Description
Research steps: If the patients with hemifacial spasm are complicated with hypertension and have the intention of surgical treatment, researchers would introduce the process, possible benefits and pos...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old;
- Preoperative MRI showed RVLM compression;
- Primary hemifacial spasm without other secondary factors;
- The office systolic blood pressure is higher than 140mmHg and the systolic blood pressure of ambulatory blood pressure is higher than 130mmHg;
- Sign informed consent.
Exclusion
- Secondary hypertension, such as renal hypertension, vascular hypertension, etc;
- No antihypertensive drugs were taken after admission and ambulatory blood pressure monitoring showed that the blood pressure was within the normal range;
- Pregnancy plan or lactation period during pregnancy or within 2 years;
- Patients with congestive heart failure (NYHA grade II-IV), myocardial infarction and unstable angina pectoris within 6 months before enrollment; patients with severe heart diseases, such as cardiogenic shock, arrhythmia requiring treatment, heart valve disease, etc;
- Severe cerebrovascular diseases (hypertensive encephalopathy, cerebrovascular injury, stroke, transient ischemic attack, etc.) within 6 months before admission;
- Patients with severe liver disease or dysfunction (ALT or AST \> 2 times the upper limit of normal reference value);
- Patients with renal impairment (male serum creatinine \> 2.0mg/dl (176 μ mol / L), female serum creatinine \> 1.8mg/dl (159 μ mol / L));
- Other surgical contraindications, such as coagulation disorders, severe anemia, severe pulmonary infection, persistent state of asthma, upper respiratory tract infection, uncorrected respiratory failure, diabetic ketoacidosis, hepatic encephalopathy, hepatic coma, acute cerebral infarction, etc;
- Type I diabetic patients; diabetic patients with poor glycemic control (FBG \> 11.1 mmol / L) or type 2 diabetic patients with microalbuminuria;
- Had Cushing's syndrome, coarctation of aorta, hyperthyroidism and other diseases in the past;
- Patients can not cooperate with the test and follow-up, such as mental disorders, dementia, advanced tumor, etc;
- If the antihypertensive drugs were adjusted within 2 weeks before admission, the patients were excluded or re enrolled after the blood pressure was stable for 2 weeks;
- Preoperative anesthesia score ≥ grade III;
- To screen those who participated in other clinical studies and used research drugs within 3 months before the trial, or planned to participate in other clinical studies during the trial period.
Key Trial Info
Start Date :
March 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2023
Estimated Enrollment :
260 Patients enrolled
Trial Details
Trial ID
NCT04791410
Start Date
March 1 2021
End Date
March 1 2023
Last Update
March 10 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.